Parnell Pharmaceuticals Holdings Operating Income 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings operating income from 2014 to 2018. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Parnell Pharmaceuticals Holdings Annual Operating Income
(Millions of US $) |
| 2021 |
$4 |
| 2020 |
$-1 |
| 2019 |
$2 |
| 2018 |
$5 |
| 2017 |
$-2 |
| 2016 |
$-13 |
| 2015 |
$-9 |
| 2014 |
$7 |
| 2014 |
$0 |
| 2013 |
$-5 |
| 2013 |
$0 |
| 2012 |
$-1 |
Parnell Pharmaceuticals Holdings Quarterly Operating Income
(Millions of US $) |
| 2018-06-30 |
|
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2016-12-31 |
$4 |
| 2016-09-30 |
$4 |
| 2015-12-31 |
$3 |
| 2015-09-30 |
$3 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
|
| 2014-03-31 |
$1 |
| 2013-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
